bevacizumab

Overview

Humanized monoclonal antibody against VEGF-A, used as an antiangiogenic agent across multiple solid tumors.

Evidence in the corpus

  • Referenced as a component of ARST0431-era regimens in extremity rhabdomyosarcoma treated at MSKCC 2000–2021 PMID:37315267.
  • Referenced as a prior systemic therapy agent in the cervical cancer MSK cohort (N=177); clinical outcomes were primarily analyzed for immune and HER2-targeted combinations PMID:37643132.
  • Bevacizumab was the experimental arm added to gemcitabine/cisplatin in the phase 3 CALGB 90601 (Alliance) trial (NCT00942331) for first-line metastatic urothelial carcinoma (BLCA). The trial showed no OS benefit for the bevacizumab arm (median OS 14 mo vs 16 mo, PFS 7.8 vs 7.6 mo). A 201-patient cfDNA biomarker substudy used this trial cohort to evaluate DDR alterations, ctDNA VAF, and TERT/PIK3CA/ERBB2 as prognostic features for cisplatin-based chemotherapy outcomes. PMID:40256659
  • Atezolizumab+bevacizumab combination showed significant PFS benefit over sunitinib for ICI/ICI-combo-preferred ccRCC patients (IMmotion151, p=0.00005; ICI responder HR=-0.52, p=0.003) in the HiTME molecular subtyping study PMID:22138691
  • Noted in the clinical-context discussion of GBM treatment in the TCGA 2013 multi-platform study (n=543); bevacizumab is cited as part of the GBM therapeutic landscape but is not the focus of biomarker analysis in this dataset PMID:24120142.
  • Reviewed in HCC: atezolizumab + bevacizumab achieved ORR 65% in 23 patients (FDA breakthrough designation); bevacizumab contributes VEGF blockade alongside anti-PD-L1 in combination strategies PMID:24798001
  • Bevacizumab + sintilimab achieved ORR 54.5% in platinum-refractory ICI-naïve R/M NPC PMID:24952746

Resistance mechanisms

  • Not reported in corpus.

Cancer types (linked)

  • RMS, ARMS
  • BLCA — metastatic urothelial carcinoma; CALGB 90601 experimental arm (null result for bevacizumab addition to gemcitabine/cisplatin).

Sources

  • PMID:37315267
  • PMID:37643132
  • PMID:40256659 — Guercio et al. (2025). CALGB 90601 cfDNA biomarker study in mUC; bevacizumab as the experimental arm (null result) in first-line gemcitabine/cisplatin ± bevacizumab.

This page was processed by crosslinker on 2026-05-09. - PMID:22138691

This page was processed by crosslinker on 2026-05-09. - PMID:24120142

This page was processed by crosslinker on 2026-05-09. - PMID:24798001

This page was processed by wiki-cli on 2026-05-11. - PMID:24952746

This page was processed by wiki-cli on 2026-05-11.